Recombinant Human ApoA1 (C-6His)

Recombinant Human ApoA1 (C-6His)

Size1:10μg price1:$52
Size2:50μg price2:$108
Size3:500μg price3:$685
SKU: PEH0082 Category: Target Proteins Tags: ,

Datasheet

Name

Recombinant Human ApoA1 (C-6His)

Purity

Greater than 95% as determined by reducing SDS-PAGE

Endotoxin level

<1 EU/µg as determined by LAL test.

Construction

Recombinant Human Apolipoprotein A-I is produced by our E.coli expression system and the target gene encoding Arg19-Gln267 is expressed with a 6His tag at the C-terminus.

Accession #

P02647

Host

E.coli

Species

Human

Predicted Molecular Mass

30.2 KDa

Buffer

Lyophilized from a 0.2 μm filtered solution of 20mM PB, 6% Sucrose, 4% Mannitol, 50mM Nacl, 0.05% Tween 80, pH7.4.

Form

Lyophilized

Shipping

The product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.

Stability&Storage

Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.

Reconstitution

Always centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

 

 

 

Alternative Names

Apolipoprotein A-I; Apo-AI; ApoA-I; Apolipoprotein A1; APOA1

 

Background

Apolipoprotein A1 (APOA1) is a secreted protein which belongs to the Apolipoprotein A1/A4/E family. APOA1 is the major protein component of high density lipoprotein (HDL) in plasma. APOA1 plays a critical role in various biological processes, such as Cholesterol metabolism, Lipid metabolism and transport, Steroid metabolism. APOA1 promotes cholesterol efflux from tissues to the liver and thus helps to clear cholesterol from arteries. Defects in this gene resulted in HDL deficiencies, including Tangier disease (TGD), systemic non-neuropathic amyloidosis, premature coronary artery disease, hepatosplenomegaly and progressive muscle wasting and weakness. In addition, ApoA-I is implicated in the anti-endotoxin function of HDL via interaction with lipopolysaccharide or endotoxin.

 

Note

For Research Use Only , Not for Diagnostic Use.